EP0476544A1 - Pyrazoloquinoline derivatives - Google Patents
Pyrazoloquinoline derivatives Download PDFInfo
- Publication number
- EP0476544A1 EP0476544A1 EP91115596A EP91115596A EP0476544A1 EP 0476544 A1 EP0476544 A1 EP 0476544A1 EP 91115596 A EP91115596 A EP 91115596A EP 91115596 A EP91115596 A EP 91115596A EP 0476544 A1 EP0476544 A1 EP 0476544A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- lower alkyl
- alkyl group
- mmol
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- This invention relates to 3-aminopyrazolo[4,3-c]quinolin-4-one derivatives useful as anti-inflammatory agents and treating agents for hepatic insufficiency.
- An object of the present invention is to provide a 3-aminopyrazolo[4,3-c]quinolin-4-one derivative having excellent anti-inflammatory activity or hepatic insufficiency treating activity.
- the present invention relates to a pyrazoloquinoline derivative having the formula (I): wherein R1, R2, and R3 independently represent a hydrogen atom or a lower alkyl group; R4 represents a hydrogen atom, a lower alkyl group, a halogen-substituted lower alkyl group or a lower alkoxycarbonyl group; the dotted line means that the pyrazole ring has two conjugated double bonds; and R4 is bounded to the nitrogen atom at the 1-position or 2-position, or pharmacologically acceptable salts thereof.
- R1, R2, and R3 independently represent a hydrogen atom or a lower alkyl group
- R4 represents a hydrogen atom, a lower alkyl group, a halogen-substituted lower alkyl group or a lower alkoxycarbonyl group
- the dotted line means that the pyrazole ring has two conjugated double bonds
- R4 is bounded to the nitrogen atom at the 1-position or 2-
- the alkyl moiety in the lower alkyl, halogen-substituted lower alkyl and lower alkoxycarbonyl groups is a straight chain or branched alkyl group having from 1 to 6 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, or hexyl groups.
- the halogen-substituted lower alkyl group has from 1 to 3 halogen atoms which may be the same or different, e.g., fluorine, chlorine, bromine, or iodine atoms.
- Salts of the compounds of formula (I) preferably include pharmacologically acceptable acid addition salts.
- the pharmacologically acceptable acid addition salts of the compound of formula (I) include inorganic acid salts, e.g., hydrochloride, sulfate, or phosphate; and organic acid salts, e.g., acetate, maleate, fumarate, tartrate, and citrate.
- the compounds of formula (I) can be prepared, for example, by Processes (a) to (e) illustrated below.
- R1, R2, R3 and R4 have the same significance as defined above;
- R 4a represents lower alkyl, halogen-substituted lower alkyl or lower alkoxycarbonyl groups in the definition of R4;
- R 3a represents a lower alkyl group in the definition of R3.
- Step 1 of (a) 1 mol of compound (II) is reacted with 2 to 5 mols of hydrazine hydrate in an alcohol solvent, e.g., methanol, ethanol, or propanol, at room temperature to 100°C for 0.5 to 3 hours.
- an alcohol solvent e.g., methanol, ethanol, or propanol
- Step 2 of (a) 1 mol of compound (III) is reacted with 1 to 5 mols of an isothiocyanate (R2-NCS) in a solvent, e.g., dimethylformamide, pyridine, dimethylacetamide, or dimethyl sulfoxide to obtain compound (Ia).
- a solvent e.g., dimethylformamide, pyridine, dimethylacetamide, or dimethyl sulfoxide.
- compound (Ib) or (Ic) is obtained by displacing a hydrogen atom of the pyrazole ring of compound (Ia) with an alkyl group or an alkoxycarbonyl group.
- Alkylating agents for introduction of an alkyl group include alkyl halides, e.g., methyl iodide, ethyl iodide, propyl iodide, isopropyl iodide, butyl iodide, or butyl bromide.
- Introduction of an alkoxycarbonyl group is preferably effected by using methyl chlorocarbonate or ethyl chlorocarbonate.
- a solvent e.g., dimethylformamide, dimethylacetamide, or dioxane
- a deacidifying agent e.g., sodium hydride, potassium carbonate, sodium carbonate, triethylamine, or pyridine.
- Pyridine may also serve as a solvent.
- reaction of process (b) generally produces compound (Ib) as a main product. Separation of compound (Ib) from compound (Ic), unreacted components and other products can be performed by usual purification means such as silica gel column chromatography.
- Step 1 of (c) is carried out by treating compound (IV) with phosphorus oxychloride at room temperature to 140°C for 1 to 5 hours to obtain compound (V).
- Step 2 of (c) 1 mol of compound (V) is reacted with 2 to 5 mols of a substituted hydrazine (R4NHNH2) in an alcohol solvent, e.g., methanol, ethanol, propanol, or 2-methoxy-ethanol.
- R4NHNH2 a substituted hydrazine
- an alcohol solvent e.g., methanol, ethanol, propanol, or 2-methoxy-ethanol.
- R4NHNH2 a substituted hydrazine
- the reaction is performed at room temperature to 100°C for 1 to 5 hours.
- the reaction products, compound (Id) and compound (Ie) can be separated into each component by usual purification techniques, such as silica gel column chromatography.
- a mono- or disubstituted compound (If) can be obtained by reacting compound (Ib) or (Id) with an alkylating agent, preferably in the presence of a deacidifying agent.
- Alkylating agents to be used include alkyl halides of the above-mentioned (b).
- the alkylating agent is used in an amount of 1 to 10 mols per mol of compound (Ib) or (Id) in a solvent, e.g., pyridine, dimethylformamide or dimethylacetamide.
- the reaction is preferably carried out at room temperature to 100°C for 1 to 10 hours.
- Suitable deacidifying agents are potassium carbonate, sodium carbonate, triethylamine, or pyridine.
- compound (Ig) can be obtained according to the same procedure as process (d) except that compound (Ic) or (Ie) are used instead of compound (Ib) or (Id).
- compound (I) in the form of a salt When compound (I) in the form of a salt is desired, a product obtained in the form of a salt is purified as such, or a product obtained in the free form is converted to its salt by dissolving or suspending it in an appropriate solvent and adding an acid thereto.
- Some compounds (I) or their pharmacologically acceptable salts exist in the form of an addition product with water or various solvents. Such addition products are also included in the scope of the present invention.
- Compound (I) or pharmacologically acceptable salts thereof can be used as it is or in various forms of preparations. Preparations can be obtained by uniformly mixing an effective amount of compound (I) or a pharmacologically acceptable salt thereof as an active ingredient with pharmacologically acceptable carriers.
- the preparations preferably have a unit dose form suitable for oral administration or injection.
- liquid preparations e.g., suspensions or syrups
- saccharides e.g., sucrose, sorbitol, or fructose
- glycols e.g., polyethylene glycol or propylene glycol
- oils e.g., sesame oil, olive oil, or soybean oil
- antiseptics e.g., p-hydroxybenzoic esters
- flavors e.g., strawberry flavor or peppermint.
- Powders, pills, capsules, or tablets can be prepared by using vehicles, e.g., lactose, glucose, sucrose, or mannitol; disintegrators, e.g., starch or sodium alginate; lubricants, e.g., magnesium stearate or talc; binders, e.g., polyvinyl alcohol, hydroxypropyl cellulose, or gelatin; surface active agents, e.g., fatty acid esters; or plasticizers, e.g., glycerin. Tablets or capsules are the most useful unit dose forms for oral administration because of their ease of application. For preparation of tablets or capsules, solid carriers are employed.
- Injectable solutions can be prepared by using carriers, such as distilled water, a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution.
- carriers such as distilled water, a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution.
- the compound is dissolved in an appropriate pharmaceutically acceptable solvent, e.g., ethyl alcohol or a mixture of ethyl alcohol and a miscible solvent, and the solution is mixed with a pharmaceutically acceptable atomizing base.
- an appropriate pharmaceutically acceptable solvent e.g., ethyl alcohol or a mixture of ethyl alcohol and a miscible solvent
- the effective dose level and number of doses of compound (I) or a pharmacologically acceptable salt thereof vary depending on the administration route and the age, body weight and symptoms of a patient.
- a recommended daily dose is usually 1 to 50 mg/kg in 3 to 4 divided doses.
- Compound 1 50 mg Lactose 113 mg Potato starch 30 mg Hydroxypropyl cellulose 6 mg Magnesium stearate 0.6 mg
- a powder was prepared from the following components in a usual manner.
- Compound 1 50 mg Lactose 750 mg
- a syrup was prepared from the following components in a usual manner.
- Compound 1 50 mg Purified sugar 75 mg Ethyl p-hydroxybenzoate 100 mg Propyl p-hydroxybenzoate 25 mg Strawberry flavor 0.25 cc Water to make 100 cc
- Capsules were prepared from the following composition in a usual manner.
- Compound 150 mg Microcrystalline cellulose 69.5 mg Magnesium stearate 0.5 mg
- An injectable solution was prepared from the following components in a usual manner.
- Compound 1 10 mg Buffer adequate amount Water to make 1.0 ml
- IgG was purified from rabbit anti-OA serum prepared in advance by the method of Koda et al. [Folia Pharmacol., Japon, 66 , 237 (1970)] in the following manner. A saturated solution of ammonium sulfate (half volume of the serum) was added to the anti-OA serum, and the mixture was left for one hour at 4°C. The precipitate was taken by centrifugation (3,000 rpm, 30 min, 4°C) and dissolved in phosphate buffered saline of Dulbecco. Then, ammonium sulfate fractionation was carried out three times in the same manner as above, whereby a purified IgG fraction was obtained.
- mice Male Wister rats weighing 225 - 250 g were pre-bred for several days and fasted overnight prior to experiment.
- the test compound (100 mg/kg) was orally administered to the animals, and after 30 minutes, IgG of rabbit anti-OA (0.2 ml, 5 mg protein/ml) was injected into the pleural cavity of the animals under anesthesia with ether. Thirty minutes after the injection of IgG, OA (albumin egg grade III; Sigma Chemical Co.) was intravenously injected into the animals as an inducer of pleurisy. After two hours, Evans Blue (25 mg/kg) was intravenously injected, and four and half hours after the injection of pleurisy, the animals were killed by bleeding.
- IgG rabbit anti-OA
- OA albumin egg grade III
- Evans Blue 25 mg/kg was intravenously injected, and four and half hours after the injection of pleurisy, the animals were killed by bleeding.
- 3-aminopyrazolo[4,3-c]quinolin-4-one derivatives exhibiting excellent anti-inflammatory activity and hepatic insufficiency treating activity.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
wherein R¹, R², and R³ independently represent a hydrogen atom or a lower alkyl group; R⁴ represents a hydrogen atom, a lower alkyl group, a halogen-substituted lower alkyl group, or a lower alkoxycarbonyl group; the dotted line means that the pyrazole ring has two conjugated double bonds; and R⁴ is bonded to the nitrogen atom at the 1-position or 2-position, or pharmacologically acceptable salts thereof. These compounds exhibit excellent anti-inflammatory activity and hepatic insufficiency treating activity.
Description
- This invention relates to 3-aminopyrazolo[4,3-c]quinolin-4-one derivatives useful as anti-inflammatory agents and treating agents for hepatic insufficiency.
- Compounds having a 3-aminopyrazol[4,3-c]quinolin-2-one skeleton are unknown. 3-Amino-6,7,8,9-tetrahydropyrazolo[(4,3-c]quinolin-4-one derivatives represented by formula:
wherein R represents a hydrogen atom or a methyl group, which are deemed structurally relevant to the compounds of the present invention are described in Journal of Chemical Society, Pirkin I, p. 857 (1978), but their pharmacological activities are entirely unknown. - An object of the present invention is to provide a 3-aminopyrazolo[4,3-c]quinolin-4-one derivative having excellent anti-inflammatory activity or hepatic insufficiency treating activity.
- The present invention relates to a pyrazoloquinoline derivative having the formula (I):
wherein R¹, R², and R³ independently represent a hydrogen atom or a lower alkyl group; R⁴ represents a hydrogen atom, a lower alkyl group, a halogen-substituted lower alkyl group or a lower alkoxycarbonyl group; the dotted line means that the pyrazole ring has two conjugated double bonds; and R⁴ is bounded to the nitrogen atom at the 1-position or 2-position, or pharmacologically acceptable salts thereof. These compounds are hereinafter collectively referred to as the compounds of formula (I) or compound (I). - In formula (I), the alkyl moiety in the lower alkyl, halogen-substituted lower alkyl and lower alkoxycarbonyl groups is a straight chain or branched alkyl group having from 1 to 6 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, or hexyl groups.
- The halogen-substituted lower alkyl group has from 1 to 3 halogen atoms which may be the same or different, e.g., fluorine, chlorine, bromine, or iodine atoms.
- Salts of the compounds of formula (I) preferably include pharmacologically acceptable acid addition salts.
- The pharmacologically acceptable acid addition salts of the compound of formula (I) include inorganic acid salts, e.g., hydrochloride, sulfate, or phosphate; and organic acid salts, e.g., acetate, maleate, fumarate, tartrate, and citrate.
-
- For the sake of convenience, these tautomers will hereinafter be inclusively represented by formula (I-1).
-
- In the above formulae, the definition of R¹, R², R³ and R⁴ have the same significance as defined above; R4a represents lower alkyl, halogen-substituted lower alkyl or lower alkoxycarbonyl groups in the definition of R⁴; and R3a represents a lower alkyl group in the definition of R³.
- In Step 1 of (a), 1 mol of compound (II) is reacted with 2 to 5 mols of hydrazine hydrate in an alcohol solvent, e.g., methanol, ethanol, or propanol, at room temperature to 100°C for 0.5 to 3 hours. Thus compound (III) can be obtained.
- Compound (II) wherein R¹ is a methyl group is known as disclosed in Indian J. Chem. Section B, 24B(1), 62 (1985). Compound (II) wherein R¹ is other than a methyl group can be synthesized according to the process disclosed therein.
- In Step 2 of (a), 1 mol of compound (III) is reacted with 1 to 5 mols of an isothiocyanate (R²-NCS) in a solvent, e.g., dimethylformamide, pyridine, dimethylacetamide, or dimethyl sulfoxide to obtain compound (Ia). The reaction is carried out at 50 to 130°C for 3 to 40 hours preferably first at 50 to 70°C for about 1 to 3 hours and then at an elevated temperature of 90 to 130°C for 3 to 40 hours.
- In process (b), compound (Ib) or (Ic) is obtained by displacing a hydrogen atom of the pyrazole ring of compound (Ia) with an alkyl group or an alkoxycarbonyl group.
- Alkylating agents for introduction of an alkyl group include alkyl halides, e.g., methyl iodide, ethyl iodide, propyl iodide, isopropyl iodide, butyl iodide, or butyl bromide. Introduction of an alkoxycarbonyl group is preferably effected by using methyl chlorocarbonate or ethyl chlorocarbonate. From 1 to 10 mols of the alkylating or alkoxycarbonylating agent is reacted with per mol of compound (Ia) in a solvent, e.g., dimethylformamide, dimethylacetamide, or dioxane at room temperature to 50°C for 1 to 20 hours. To accelerate the reaction, the reaction may be carried out in the presence of a deacidifying agent, e.g., sodium hydride, potassium carbonate, sodium carbonate, triethylamine, or pyridine. Pyridine may also serve as a solvent.
- The reaction of process (b) generally produces compound (Ib) as a main product. Separation of compound (Ib) from compound (Ic), unreacted components and other products can be performed by usual purification means such as silica gel column chromatography.
- Step 1 of (c) is carried out by treating compound (IV) with phosphorus oxychloride at room temperature to 140°C for 1 to 5 hours to obtain compound (V).
- Compound (IV) wherein R¹ is a methyl group is known as described in J. Heterocycl. Chem., 16(8), 1605 (1979). Other compounds (IV) are synthesized according to the process disclosed therein.
- In Step 2 of (c), 1 mol of compound (V) is reacted with 2 to 5 mols of a substituted hydrazine (R⁴NHNH₂) in an alcohol solvent, e.g., methanol, ethanol, propanol, or 2-methoxy-ethanol. Thus, compound (Id) and (Ie) are obtained. The reaction is performed at room temperature to 100°C for 1 to 5 hours. The reaction products, compound (Id) and compound (Ie), can be separated into each component by usual purification techniques, such as silica gel column chromatography.
- In process (d), a mono- or disubstituted compound (If) can be obtained by reacting compound (Ib) or (Id) with an alkylating agent, preferably in the presence of a deacidifying agent. Alkylating agents to be used include alkyl halides of the above-mentioned (b). The alkylating agent is used in an amount of 1 to 10 mols per mol of compound (Ib) or (Id) in a solvent, e.g., pyridine, dimethylformamide or dimethylacetamide. The reaction is preferably carried out at room temperature to 100°C for 1 to 10 hours. Suitable deacidifying agents are potassium carbonate, sodium carbonate, triethylamine, or pyridine.
- In process (e), compound (Ig) can be obtained according to the same procedure as process (d) except that compound (Ic) or (Ie) are used instead of compound (Ib) or (Id).
- All the intermediate products and desired products obtained in the above-described processes can be isolated and purified by purification techniques commonly employed in organic synthesis, such as filtration, extraction, washing, drying, concentration, recrystallization, or chromatographic methods. Alternatively, the intermediate product may be subsequently reacted as is without purification.
- When compound (I) in the form of a salt is desired, a product obtained in the form of a salt is purified as such, or a product obtained in the free form is converted to its salt by dissolving or suspending it in an appropriate solvent and adding an acid thereto.
- Some compounds (I) or their pharmacologically acceptable salts exist in the form of an addition product with water or various solvents. Such addition products are also included in the scope of the present invention.
-
- Compound (I) or pharmacologically acceptable salts thereof can be used as it is or in various forms of preparations. Preparations can be obtained by uniformly mixing an effective amount of compound (I) or a pharmacologically acceptable salt thereof as an active ingredient with pharmacologically acceptable carriers. The preparations preferably have a unit dose form suitable for oral administration or injection.
- For preparation of dose forms for oral administration, any useful and pharmacologically acceptable carriers can be used. For example, liquid preparations, e.g., suspensions or syrups, can be prepared by using water, saccharides, e.g., sucrose, sorbitol, or fructose; glycols, e.g., polyethylene glycol or propylene glycol; oils, e.g., sesame oil, olive oil, or soybean oil; antiseptics, e.g., p-hydroxybenzoic esters; or flavors, e.g., strawberry flavor or peppermint. Powders, pills, capsules, or tablets can be prepared by using vehicles, e.g., lactose, glucose, sucrose, or mannitol; disintegrators, e.g., starch or sodium alginate; lubricants, e.g., magnesium stearate or talc; binders, e.g., polyvinyl alcohol, hydroxypropyl cellulose, or gelatin; surface active agents, e.g., fatty acid esters; or plasticizers, e.g., glycerin. Tablets or capsules are the most useful unit dose forms for oral administration because of their ease of application. For preparation of tablets or capsules, solid carriers are employed.
- Injectable solutions can be prepared by using carriers, such as distilled water, a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution.
- For an aerosol for inhalation, the compound is dissolved in an appropriate pharmaceutically acceptable solvent, e.g., ethyl alcohol or a mixture of ethyl alcohol and a miscible solvent, and the solution is mixed with a pharmaceutically acceptable atomizing base.
- The effective dose level and number of doses of compound (I) or a pharmacologically acceptable salt thereof vary depending on the administration route and the age, body weight and symptoms of a patient. A recommended daily dose is usually 1 to 50 mg/kg in 3 to 4 divided doses.
- The present invention is now illustrated in greater detail with reference to the following Examples.
- In 140 ml of ethanol was dissolved 6.02 g (27 mmol) of 4-chloro-1-propylquinolin-2(1H)-one, and 140 ml of hydrazine monohydrate was added thereto, followed by refluxing for 3 hours. The reaction mixture was concentrated to an about half of its original volume and then allowed to cool to obtain 5.53 g (94%) of the titled compound as a pale yellow crystal.
Melting point: 181-186°CElementary Analysis for C₁₂H₁₅N₃O: Calcd. (%): C 66.34; H 6.96; N 19.34 Found (%): C 66.50, H 7.18; N 19.62
IR (KBr) Vmax (cm⁻¹): 1642, 748
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.12 (1H, s), 7.94-7.91 (1H, m), 7.57-7.50 (1H, m), 7.43-7.40 (1H, m), 7.16-7.10 (1H, m), 5.86 (1H, s), 4.24 (2H, brs), 4.13-4.07 (2H, m), 1.62-1.53 (2H, m), 0.92 (3H, t, J=7Hz) - In 10 ml of phosphorus oxychloride was refluxed 1.0 g (4.1 mmol) of 1,2-dihydro-4-hydroxy-1-propyl-2-oxo-3-quinolinecarbonitrile for 1 hour. The reaction mixture was dried under reduced pressure, and the residue was partitioned between chloroform and water. The chloroform layer was dried under reduced pressure to obtain 0.44 g (41%) of the titled compound as a yellow crystal.
Melting point: 203-205°CElementary Analysis for C₁₃H₁₁CℓN₂O: Calcd. (%): C 63.29; H 4.49; N 11.36 Found (%): C 63.23, H 4.33; N 11.45
IR (KBr)νmax (cm⁻¹): 2232, 1645, 762
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.12-8.08 (1H, m), 7.94-7.87 (1H, m), 7.79-7.76 (1H, m), 7.53-7.47 (1H, m), 4.27-4.22 (2H, m), 1.71-1.63 (2H, m), 0.97 (3H, t, J=7Hz) - In 18 ml of N,N-dimethylformamide (DMF), 2.08 g (9.6 mmol) of Compound a prepared in Example 1 and 1.59 g (21.7 mmol) of methylthioisocyanate were stirred at 140°C for 20 hours. Water was added to the reaction mixture, and the mixture was cooled and allowed to stand. The crystal thus formed was washed with ethyl acetate and then recrystallized from DMF-ethanol to obtain 0.76 g (30%) of the titled compound as a pale yellow crystal.
Melting point: 267-270°CElementary Analysis for C₁₄H₁₆N₄O: Calcd. (%): C 65.60; H 6.29; N 21.86 Found (%): C 65.39; H 6.58; N 21.71
IR (KBr) νmax (cm⁻¹): 1645, 748
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 12.68 (1H, brs), 8.04-8.01 (1H, m), 7.57-7.51 (2H, m), 7.28-7.23 (1H, m), 5.53 (1H, brs), 4.20-4.14 (2H, m), 2.88 (3H, d, J=5Hz), 2.56-2.49 (2H, m), 0.94 (3H, t, J=7Hz)
MS, m/e: 256 (M⁺) - In 150 ml of DMF, 15.0 g (69 mmol) of Compound a and 18.9 g (157 mmol) of butylthioisocyanate were stirred at 140°C for 40 hours. Water was added to the reaction mixture, followed by cooling. The precipitate thus formed was subjected to silica gel column chromatography using a 30:1 (by volume) mixed solvent of chloroform and methanol as an eluent. The main fraction was collected, dried under reduced pressure, and recrystallized from water-containing ethanol to obtain 2.0 g (10 %) of the titled compound as a pale yellow crystal.
Melting point: 169-172°C
IR (KBr) νmax (cm⁻¹): 1660, 1581, 747
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 12.6 (1H, brs), 8.03-8.00 (1H, m), 7.58-7.52 (2H, m), 7.29-7.23 (1H, m), 5.60 (1H, brs), 4.19-4.13 (2H, m), 3.30-3.25 (2H, m), 1.70-1.54 (4H, m), 1.44-1.30 (2H, m), 0.97-0.87 (6H, m)
MS, m/e: 298 (M⁺) - In 70 ml of DMF was suspended 1.69 g (6.6 mmol) of Compound 1, and 0.33 g (8.3 mmol) of 60% sodium hydride was added and dissolved therein. To the mixture was added 0.80 ml (10 mmol) of methyl chlorocarbonate, followed by stirring at room temperature for 1 hour. The reaction mixture was dried under reduced pressure, and the residue was partitioned between chloroform and water. The chloroform layer was dried under reduced pressure, passed through a silica gel column, and eluted with chloroform. The main fraction collected was dried under reduced pressure and recrystallized from water-containing ethanol to obtain 1.03 g (50%) of the titled compound as a colorless crystal.
Melting point: 160-163°CElementary Analysis for C₁₆H₁₈N₄O₃: Calcd. (%): C 61.13; H 5.77; N 17.82 Found (%): C 61.08, H 6.01; N 17.94
IR (KBr) νmax (cm⁻¹): 1749, 1660
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.93-8.89 (1H, m), 7.69-7.67 (2H, m), 7.35-7.29 (1H, m), 6.26 (1H, brq, J=5Hz), 4.30-4.24 (2H, m), 4.02 (3H, s), 2.90 (3H, d, J=5Hz), 1.72-1.63 (2H, m), 0.96 (3H, t, J=7Hz)
MS, m/e: 314 (M⁺) - In 70 ml of DMF was suspended 1.00 g (3.9 mmol) of Compound 1, and 0.20 g (5.0 mmol) of 60% sodium hydride was added and dissolved therein. To the mixture was added 0.88 ml (7.7 mmol) of butyl iodide, followed by stirring at room temperature for 1 hour. The reaction mixture was dried under reduced pressure, and the residue was partitioned between chloroform and water. The chloroform layer was dried under reduced pressure, passed through a silica gel column, and eluted with chloroform. The main fraction collected was dried under reduced pressure and recrystallized from water-containing ethanol to obtain 0.55 g (45%) of the titled compound as a colorless crystal.
Melting point: 125-127°C
IR (KBr) νmax (cm⁻¹): 1645, 750
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.06-8.03 (1H, m), 7.60-7.55 (2H, m), 7.36-7.30 (1H, m), 4.45 (2H, t, J=7Hz), 4.22-4.17 (2H, m), 2.88 (3H, s), 1.83-1.59 (4H, m), 1.42-1.34 (2H, m), 0.95 (3H, t, J=7Hz), 0.92 (3H, t, J=7Hz)
MS, m/e: 312 - In 60 ml of dioxane was suspended 1.40 g (4.7 mmol) of Compound 2, and 1.0 ml (7.2 mmol) of triethylamine and 0.73 ml (9.4 mmol) of methyl chlorocarbonate were added thereto, followed by stirring at room temperature for 2 hours. The reaction mixture was dried under reduced pressure, and the residue was partitioned between chloroform and water. The chloroform layer was dried under reduced pressure, and the residue was passed through a silica gel column and eluted with a 3:1 (by volume) mixed solvent of hexane and ethyl acetate. The main fraction collected was recrystallized from hexaneethyl acetate to obtain 0.67 g (40%) of the titled compound as a colorless crystal.
Melting point: 147-149°C
IR (KBr) νmax (cm⁻¹): 1740, 1661, 762
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.93-8.90 (1H, m), 7.70-7.67 (2H, m), 7.36-7.30 (1H, m), 6.14 (1H, brt, J=6Hz), 4.30-4.27 (2H, m), 4.02 (3H, s), 3.35-3.23 (2H, m), 1.72-1.57 (4H, m), 1.43-1.34 (2H, m), 0.97 (3H, s, J=7Hz), 0.93 (3H, s, J=7Hz)
MS, m/e: 356 (M⁺) - In 60 ml of methanol were refluxed 2.00 g (8.1 mmol) of Compound b prepared in Example 2 and 1.10 g (12.2 mmol) of methoxycarbonylhydrazine for 6 hours. The reaction mixture was cooled to obtain 1.32 g (54%) of the titled compound as a colorless crystal.
Melting point: 180-184°CElementary Analysis for C₁₅H₁₆N₄O₃: Calcd. (%): C 59.99; H 5.37; N 18.66 Found (%): C 60.21, H 5.42; N 18.36
IR (KBr) νmax (cm⁻¹): 1746, 1651
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.03-8.00 (1H, m), 7.61-7.54 (1H, m), 7.47-7.44 (1H, m), 7.36 (2H, brs), 7.26-7.21 (1H, m), 4.14-4.08 (2H, m), 4.02 (3H, s), 1.67-1.62 (2H, m), 0.95 (3H, t, J=7Hz)
MS, m/e: 300 (M⁺) - In a mixture of 60 ml of ethanol and 5 ml of triethylamine, 2.00 g (8.1 mmol) of Compound b and 2.00 g (16 mmol) of t-butylhydrazine hydrochloride were refluxed for 4 hours. The reaction mixture was dried under reduced pressure, and the residue was partitioned between chloroform and water. The chloroform layer was dried under reduced pressure, and the residue was passed through a silica gel column and eluted with a 3:1 (by volume) mixed solvent of hexane and ethyl acetate. The main fraction collected was dried under reduced pressure to obtain 2.11 g (87%) of Compound 7 as a colorless crystal. The product was treated with ethyl acetate saturated with hydrogen chloride to obtain a hydrochloride of Compound 7.
Melting point: 175-177°CElementary Analysis for C₁₇H₂₂N₄O·HCℓ: Calcd. (%): C 60.98; H 6.92; N 16.73 Found (%): C 61.10, H 7.22; N 16.80
IR (KBr) νmax (cm⁻¹): 1662, 760
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.00-7.97 (1H, m), 751-7.41 (2H, m), 7.22-7.16 (1H, m), 6.17 (2H, brs), 4.15-4.10 (2H, m), 1.71-1.58 (2H, m), 1.65 (9H, s), 0.94 (3H, t, J=7Hz)
MS, m/e: 298 (M⁺) - In 60 ml of ethanol, 2.00 g (8.1 mmol) of Compound b and 1.94 ml (16 mmol) of 2,2,2-trifluoroethylhydrazine were refluxed for 6 hours. The reaction mixture was cooled to obtain 1.73 g (66%) of a colorless crystal. The product was treated with ethyl acetate saturated with hydrogen chloride to obtain a hydrochloride.
Melting point: 235-237°CElementary Analysis for C₁₅H₁₅F₃N₄O·HCℓ: Calcd. (%): C 49.94; H 4.47; N 15.53 Found (%): C 50.23, H 4.40; N 15.18
IR (KBr) νmax (cm⁻¹): 1640, 766
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 7.97-7.94 (1H, m), 7.54-7.42 (2H, m), 7.23-7.17 (1H, m), 6.81 (2H, brs), 5.10 (2H, q, J=9Hz), 4.16-4.10 (2H, m), 1.70-1.56 (2H, m), 0.95 (3H, t, J=7Hz)
MS, m/e: 324 (M⁺) - In 150 ml of DMF was dissolved 2.26 g (7.0 mmol) of a hydrochloride of Compound 8 obtained in Example 10, and 0.42 g (11 mmol) of 60% sodium hydride was added to the solution. After stirring at room temperature for 30 minutes, 0.87 ml (14 mmol) of methyl iodide was added thereto, followed by stirring for 1 hour. The reaction mixture was dried under reduced pressure, and the residue was partitioned between chloroform and water. The chloroform layer was dried under reduced pressure, and the residue was passed through a silica gel column and eluted with chloroform. The first main fraction collected was dried under reduced pressure to obtain 0.65 g (25%) of Compound 9 as a colorless crystal.
Melting point: 142.5-145.5°CElementary Analysis for C₁₇H₁₉F₃N₄O: Calcd. (%): C 57.95; H 5.43; N 15.90 Found (%): C 57.97, H 5.10; N 15.90
IR (KBr) νmax (cm⁻¹): 1661, 1174, 747
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.14-8.11 (1H, m), 7.62-7.52 (2H, m), 7.31-7.25 (1H, m), 5.21 (2H, q, J=9Hz), 4.24-4.18 (2H, m), 2.86 (6H, s), 1.71-1.62 (2H, m), 0.98 (3H, t, J=7Hz)
MS, m/e: 352 (M⁺), 337, 323 - The second main fraction was collected and dried under reduced pressure to obtain 1.10 g (47%) of a colorless crystal (Compound 10), which was then treated with ethyl acetate saturated with hydrogen chloride to obtain a hydrochloride of Compound 10.
Melting point: 168.0-168.5°C
IR (KBr) νmax (cm⁻¹): 3324, 1616, 1159, 752
¹H-NMR (DMSO-d₆, 270 MHz) δ (ppm): 8.01-7.97 (1H, m), 7.53-7.40 (2H, m), 7.22-7.16 (1H, m), 5.13 (2H, q, J=9Hz), 4.15-4.09 (2H, m), 3.90 (brs, 1H), 3.27 (3H, s), 1.66-1.58 (2H, m), 0.96 (3H, t, J=7Hz)
MS, m/e: 338 (M⁺), 309, 296 - Tablets were prepared from the following components in a usual manner.
Compound 1 50 mg Lactose 113 mg Potato starch 30 mg Hydroxypropyl cellulose 6 mg Magnesium stearate 0.6 mg - A powder was prepared from the following components in a usual manner.
Compound 1 50 mg Lactose 750 mg - A syrup was prepared from the following components in a usual manner.
Compound 1 50 mg Purified sugar 75 mg Ethyl p-hydroxybenzoate 100 mg Propyl p-hydroxybenzoate 25 mg Strawberry flavor 0.25 cc Water to make 100 cc - Capsules were prepared from the following composition in a usual manner.
Compound 150 mg Microcrystalline cellulose 69.5 mg Magnesium stearate 0.5 mg - The above components were mixed and filled in gelatin capsules.
- An injectable solution was prepared from the following components in a usual manner.
Compound 1 10 mg Buffer adequate amount Water to make 1.0 ml - Typical pharmacological activities of compound (I) are demonstrated by Examples 17 and 18.
- IgG was purified from rabbit anti-OA serum prepared in advance by the method of Koda et al. [Folia Pharmacol., Japon, 66, 237 (1970)] in the following manner.
A saturated solution of ammonium sulfate (half volume of the serum) was added to the anti-OA serum, and the mixture was left for one hour at 4°C. The precipitate was taken by centrifugation (3,000 rpm, 30 min, 4°C) and dissolved in phosphate buffered saline of Dulbecco. Then, ammonium sulfate fractionation was carried out three times in the same manner as above, whereby a purified IgG fraction was obtained. - Male Wister rats weighing 225 - 250 g were pre-bred for several days and fasted overnight prior to experiment. The test compound (100 mg/kg) was orally administered to the animals, and after 30 minutes, IgG of rabbit anti-OA (0.2 ml, 5 mg protein/ml) was injected into the pleural cavity of the animals under anesthesia with ether. Thirty minutes after the injection of IgG, OA (albumin egg grade III; Sigma Chemical Co.) was intravenously injected into the animals as an inducer of pleurisy. After two hours, Evans Blue (25 mg/kg) was intravenously injected, and four and half hours after the injection of pleurisy, the animals were killed by bleeding.
Then, an exudate in the pleural cavity was obtained, and the volume of the exudate was measured. The pleural cavity was rinsed with 5 ml of physiological saline and the rinsings were added to the exudate. The number of infiltrated cells in the mixture was counted and th volume of the dye in the mixture was determined by the absorption at 625 nm [Agents and Actions, 25, 326 (1988)]. The suppression rates for the volume of the exudate, the number of infiltrated cells and the volume of the dye in the pleural cavity were calculated by the following equation. - S.V:
- the value obtained with the group administered with the test compound and in which pleurisy is induced
- N.V:
- the value obtained with the group in which pleurisy is not induced
- P.V:
- the value obtained with the group administered with no test compound and in which pleurisy is induced
- Effect of test compounds on hepatic insufficiency was measured by the following method [Acta. Hepatol. Japon, 26, 1438 (1985)]. Blood cells of Propionibacterium acnes (1 mg/mouse) was applied to 8-week-old male BALB/c mice (30 mice per group) by intravenous injection at the tail. After 7 days, 1 µg/mouse of lipopolysaccharide from Salmonella enteritidis was intravenously injected to induce acute hepatic insufficiency. At the same time, 100 mg/kg of compound (I) suspended in 0.3% carboxymethyl cellulose (CMC) was orally administered to mice (only 0.3% CMC was given to the control group). Mortality of animals were measured at 7 and 24 hours following the injection of lipopolysaccharide. The suppression effect of mortality of mice due to hepatic insufficiency were shown in Table 4. In Table 4, the value are calculated based on the decrease in mortality from control (untreated mice).
TABLE 4 INHIBITION OF MORTALITY OF MICE DUE TO HEPATIC INSUFFICIENCY Compound No. Mortality At 7 Hrs. At 24 Hrs. 1 39.2 17.9 3 42.0 13.9 Control 86.7 96.7 - According to the present invention, there are provided 3-aminopyrazolo[4,3-c]quinolin-4-one derivatives exhibiting excellent anti-inflammatory activity and hepatic insufficiency treating activity.
INHIBITION OF ALLERGIC PLEURISY IN RATS | |||
Suppression rate (%) | |||
Compound | Volume of exudate | Volume of dye in the exudate | Number of infiltrated cells in the exudate |
3 | 8.5 | 41.2 | 48.2 |
4 | 26.4 | 45.6 | 24.1 |
* 8Sa | 52.9 | 52.3 | 36.2 |
* Sa means an hydrochloride of compound 8. |
Claims (6)
- A pyrazoloquinoline derivative having the formula (I):
- A pyrazoloquinoline derivative according to claim 1, wherein R⁴ is bounded to the nitrogen atom at the 1 position; R¹ represents a lower alkyl group; and R² represents a lower alkyl group.
- A pyrazoloquinoline derivative according to claim 2, wherein R¹ represents propyl.
- A pyrazoloquinoline derivative according to claim 1, wherein R⁴ is bounded to the nitrogen atom at the 2 position; and R¹ represents a lower alkyl group.
- A pyrazoloquinoline derivative according to claim 4, wherein R¹ represents propyl.
- A pharmaceutical composition comprising the pyrazoloquinoline derivative of any of claims 1 to 5 as an active ingredient in an amount effective to treat inflammation or hepatic insufficiency and a pharmacologically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24538990 | 1990-09-14 | ||
JP245389/90 | 1990-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0476544A1 true EP0476544A1 (en) | 1992-03-25 |
EP0476544B1 EP0476544B1 (en) | 1995-05-10 |
Family
ID=17132930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91115596A Expired - Lifetime EP0476544B1 (en) | 1990-09-14 | 1991-09-13 | Pyrazoloquinoline derivatives |
Country Status (7)
Country | Link |
---|---|
US (1) | US5192768A (en) |
EP (1) | EP0476544B1 (en) |
AT (1) | ATE122351T1 (en) |
CA (1) | CA2051310C (en) |
DE (1) | DE69109592T2 (en) |
DK (1) | DK0476544T3 (en) |
ES (1) | ES2072503T3 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526840A1 (en) * | 1991-07-31 | 1993-02-10 | Kyowa Hakko Kogyo Co., Ltd. | Condensed naphthyridine derivatives |
US5281610A (en) * | 1991-07-31 | 1994-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Condensed naphthyridine derivatives |
EP0579968A1 (en) | 1992-06-27 | 1994-01-26 | Hoechst Aktiengesellschaft | 4-Iminoquinolines, processes for their preparation and their use |
WO2005028474A2 (en) * | 2003-05-29 | 2005-03-31 | Millennium Pharmaceuticals, Inc. | Pyrazoloquinoline derivatives as chk-1 inhibitors |
US7842701B2 (en) | 2004-02-19 | 2010-11-30 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
WO2012033144A1 (en) | 2010-09-07 | 2012-03-15 | アステラス製薬株式会社 | Pyrazoloquinoline compound |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127519A1 (en) * | 2002-12-12 | 2004-07-01 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
US20040142978A1 (en) * | 2002-12-12 | 2004-07-22 | Pharmacia Corporation | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |
US6909001B2 (en) * | 2002-12-12 | 2005-06-21 | Pharmacia Corporation | Method of making tricyclic aminocyanopyridine compounds |
CN111514144B (en) | 2015-05-26 | 2021-10-26 | 高雄医学大学 | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4524146A (en) * | 1982-12-08 | 1985-06-18 | Ciba-Geigy Corporation | Certain -2-heterocycle substituted pyrazoloquinolines |
US4675324A (en) * | 1984-10-26 | 1987-06-23 | Fujisawa Pharmaceutical Co., Ltd. | Substituted pyrazolo [4,3-c]pyridines and their use as uricosuric, diuretic and anti-hypertensive agents |
US4748246A (en) * | 1987-05-07 | 1988-05-31 | American Home Products Corporation | Pyrazolo(4,3-c)quinolines |
-
1991
- 1991-09-12 US US07/757,988 patent/US5192768A/en not_active Expired - Fee Related
- 1991-09-13 CA CA002051310A patent/CA2051310C/en not_active Expired - Fee Related
- 1991-09-13 DE DE69109592T patent/DE69109592T2/en not_active Expired - Fee Related
- 1991-09-13 ES ES91115596T patent/ES2072503T3/en not_active Expired - Lifetime
- 1991-09-13 DK DK91115596.8T patent/DK0476544T3/en active
- 1991-09-13 EP EP91115596A patent/EP0476544B1/en not_active Expired - Lifetime
- 1991-09-13 AT AT91115596T patent/ATE122351T1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4524146A (en) * | 1982-12-08 | 1985-06-18 | Ciba-Geigy Corporation | Certain -2-heterocycle substituted pyrazoloquinolines |
US4675324A (en) * | 1984-10-26 | 1987-06-23 | Fujisawa Pharmaceutical Co., Ltd. | Substituted pyrazolo [4,3-c]pyridines and their use as uricosuric, diuretic and anti-hypertensive agents |
US4748246A (en) * | 1987-05-07 | 1988-05-31 | American Home Products Corporation | Pyrazolo(4,3-c)quinolines |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 90, No. 7, February 12, 1979, Columbus, Ohio, USA KUMAR, ARVIND et al. "Ketene dithioacetals. Part 11. Reaction of 3-cyano-4- -methylthio-2(1H)-pyridones with hydrazine and guanidine: synthesis of novel substituted and fused pyrazolo(4,3-c)pyridone and pyrido(4,3-d)pyrimidine derivatives" page 606, column 2, abstract -No. 54 893v * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526840A1 (en) * | 1991-07-31 | 1993-02-10 | Kyowa Hakko Kogyo Co., Ltd. | Condensed naphthyridine derivatives |
US5281610A (en) * | 1991-07-31 | 1994-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Condensed naphthyridine derivatives |
EP0579968A1 (en) | 1992-06-27 | 1994-01-26 | Hoechst Aktiengesellschaft | 4-Iminoquinolines, processes for their preparation and their use |
US5602146A (en) * | 1992-06-27 | 1997-02-11 | Hoechst Aktiengesellschaft | 4-iminoquinolines, processes for their preparation, and their use |
WO2005028474A2 (en) * | 2003-05-29 | 2005-03-31 | Millennium Pharmaceuticals, Inc. | Pyrazoloquinoline derivatives as chk-1 inhibitors |
WO2005028474A3 (en) * | 2003-05-29 | 2005-06-02 | Millennium Pharm Inc | Pyrazoloquinoline derivatives as chk-1 inhibitors |
US7842701B2 (en) | 2004-02-19 | 2010-11-30 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
WO2012033144A1 (en) | 2010-09-07 | 2012-03-15 | アステラス製薬株式会社 | Pyrazoloquinoline compound |
US8822448B2 (en) | 2010-09-07 | 2014-09-02 | Astellas Pharma Inc. | Pyrazoloquinoline compound |
Also Published As
Publication number | Publication date |
---|---|
US5192768A (en) | 1993-03-09 |
ES2072503T3 (en) | 1995-07-16 |
ATE122351T1 (en) | 1995-05-15 |
DE69109592T2 (en) | 1995-10-05 |
DK0476544T3 (en) | 1995-08-07 |
EP0476544B1 (en) | 1995-05-10 |
CA2051310A1 (en) | 1992-03-15 |
CA2051310C (en) | 2001-04-10 |
DE69109592D1 (en) | 1995-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0653427A1 (en) | Galanthamine derivatives, a process for their preparation and their use as medicaments | |
EP0929551A1 (en) | New pharmaceutically active compounds | |
UA43821C2 (en) | PYRAZOLOPYRIDINE COMPOUND OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | |
KR100224135B1 (en) | Quinoline or quinoline derivatives, their production and use | |
EP0476544B1 (en) | Pyrazoloquinoline derivatives | |
PL125321B1 (en) | Process for preparing novel,condensed derivatives of pyrimidines | |
EP0459505B1 (en) | Imidazonaphthyridine derivatives | |
JPH0222075B2 (en) | ||
JPH01254678A (en) | Dihydropyridine compound | |
EP0816338B1 (en) | 3-(bis-substituted-phenylmethylene)oxindole derivatives | |
JPH07133224A (en) | Medicine for arteriosclerosis | |
EP0417790B1 (en) | S-triazolo[3,4-i]purine derivatives | |
US4495187A (en) | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | |
JP2954647B2 (en) | Hexitol derivative | |
JP2007510742A (en) | Methods and compositions for selectin inhibition | |
KR20060092220A (en) | Imidazopyridine-derivatives as inductible no-synthase inhibitors | |
JP3006925B2 (en) | Pyrazoloquinoline derivatives | |
US4547501A (en) | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | |
HU192728B (en) | Process for producing 4-oxo-pyrido/2,3-d/pyrimidine derivatives and pharmaceutical compositions containing them | |
KR100192863B1 (en) | Use of pyridoindole derivatives in the treatment of ischemic disorders | |
EP0121197B1 (en) | Pyrazolopyridine derivatives, therapeutic compositions comprising same, and process thereof | |
US3910917A (en) | 1-Oxo-hexahydroacridines | |
US4168312A (en) | Quinolone derivatives | |
KR900000367B1 (en) | Substituted isoquinoline derivatives and antiulcer agents and their preparations | |
EP0411394A1 (en) | Imidazoquinolone derivates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19920424 |
|
17Q | First examination report despatched |
Effective date: 19940513 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 122351 Country of ref document: AT Date of ref document: 19950515 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 69109592 Country of ref document: DE Date of ref document: 19950614 |
|
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2072503 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3016594 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20010906 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20010911 Year of fee payment: 11 Ref country code: FR Payment date: 20010911 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20010912 Year of fee payment: 11 Ref country code: AT Payment date: 20010912 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20010913 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20010914 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20010920 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20010927 Year of fee payment: 11 Ref country code: GR Payment date: 20010927 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20011001 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20011105 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020913 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020913 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020914 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020914 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020930 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020930 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020930 |
|
BERE | Be: lapsed |
Owner name: *KYOWA HAKKO KOGYO CO. LTD Effective date: 20020930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030401 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030404 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20020913 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030603 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20031011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050913 |